Back to Search
Start Over
Biomarkers that may predict response to immunotherapy in ovarian malignancies
- Source :
- Current opinion in obstetricsgynecology. 32(1)
- Publication Year :
- 2019
-
Abstract
- Purpose of review Immune checkpoint blockade (ICB) is a promising area of cancer therapeutic research. Therapies targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) mechanism of tumor immune evasion have resulted in durable responses in many difficult-to-treat tumor types. While these inhibitors are being actively investigated in clinical trials for ovarian cancer, most patients fail to respond to initial treatment with immune therapy. This review focuses on biomarkers for predicting response to treatment, and discusses clinical trials using ICB for recurrent ovarian cancer. Recent findings While PD-L1 detection by immunohistochemistry (IHC) is approved as a companion or complementary diagnostic in some cancers, there are many limitations with its use as a predictive marker. Recent research has explored biomarkers beyond PD-L1 that assess for somatic mutations, immune cell infiltrate, and gene signatures. Summary With improved understanding of the tumor microenvironment and genomic classifications of ovarian tumors, new diagnostics and biomarkers that supplement conventional IHC may help predict response to therapy.
- Subjects :
- Oncology
medicine.medical_specialty
medicine.medical_treatment
B7-H1 Antigen
Immune system
Internal medicine
medicine
Biomarkers, Tumor
Tumor Microenvironment
Humans
Immune Checkpoint Inhibitors
Ovarian Neoplasms
Tumor microenvironment
Predictive marker
business.industry
Obstetrics and Gynecology
Cancer
Immunotherapy
medicine.disease
Immune checkpoint
Clinical trial
Female
Neoplasm Recurrence, Local
business
Ovarian cancer
Subjects
Details
- ISSN :
- 1473656X
- Volume :
- 32
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Current opinion in obstetricsgynecology
- Accession number :
- edsair.doi.dedup.....e71b437313288e0f528f2c005ecb4b8f